No Data
Kain Technology 2024 Third Quarter Report
Kayin Technology (688687.SH) intends to acquire 5% equity of its subsidiary KayinGe Ling.
Cain Technology (688687.SH) announced that the company plans to acquire its controlling subsidiary with cash of 9.9571 million yuan.
Kaiyin Technology (688687.SH): intends to acquire 5% equity of Kaiyingling for 9.9571 million yuan.
Guolonghui, October 21st | Kaiyin Technology (688687.SH) announced that, based on the company's global strategy and business development needs, the company plans to use 9.9571 million yuan in cash to acquire 5% equity of Kaiyingeling held by Mr. Tang Jian, a minority shareholder of the controlling subsidiary, Kaiyin. The source of funds for the acquisition is the company's own money market. After the completion of this transaction, the company will hold 81% equity of Kaiyingeling. The two parties will sign the equity transfer agreement after the equity transfer matters review process is completed.
Kain Technology (688687.SH): The net income for the first three quarters was 0.108 billion yuan, a year-on-year increase of 19.74%.
On October 21, Kein Technology (688687.SH) announced that the company achieved revenue of 1.011 billion yuan in the first three quarters, a year-on-year increase of 0.82%; the net income attributable to shareholders of the listed company was 0.108 billion yuan, an increase of 19.74% year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.111 billion yuan, an increase of 16.26% year-on-year; and the basic earnings per share was 0.645 yuan.
Kyan Technology (688687.SH): The application for marketing authorization of Pei integrated interferon α-2 injection for additional indications has been accepted.
Kain technology (688687.SH) announced on September 30th that it has recently received the 'Acceptance Notice' issued by the National Medical Products Administration. The company's innovative biological product, the pegylated interferon α-2 injection (trade name: Paiyisheng), has obtained the acceptance of the National Medical Products Administration for the application for the new indication of chronic hepatitis B in adults. The pegylated interferon α-2 injection is a recombinant interferon modified by PEG. The recombinant interferon is obtained by analyzing the integration following the principle of highest homology after sequence homology comparison of more than ten natural α-interferon subtypes. Its activity is higher than that of a
Kain Technology (688687.SH): Appoints He Chongfei as Chief Financial Officer.
Kain Technology (688687.SH) announced that the board of directors of the company recently received a written communication from the company's Chief Financial Officer, Guo Wei...
No Data
No Data